Abstract
Introduction
In 2008, antiretroviral sales across the seven major markets totaled $10.7
billion, growing at a CAGR of 12.8% between 2005 and 2008. Datamonitor expects
this expansion to slow down. Despite drivers such as new product launches,
earlier treatment initiation, decreasing mortality and an increase in HIV
prevalence, a series of patent expiries will impact branded sales from 2011.
Scope of this research
- Analysis of the current and future market dynamics for antiretrovirals
across the US, EU, Japan, supported by KOL insights
- Detailed sales forecasts for the major antiretroviral classes, molecules
and brands in each of the seven major markets.
- Assessments of the key marketed antiretroviral brands and late stage
pipeline products.
- Snapshot of HIV drug sales in the Rest of World by region
Research and analysis highlights
The highest selling drug in 2008 was Truvada, with revenues of $1.9 billion
across the seven major markets, closely followed by Atripla with sales of $1.5
billion. Truvada' s success has been driven by its popularity as the backbone
of choice for highly active antiretroviral therapy (HAART) regimens across
several lines of therapy.
Several drugs are currently in Phase III development, including
Tibotec/Johnson & Johnson' s rilpivirine, Schering-Plough' s vicriviroc and
Gilead' s elvitegravir. In Datamonitor' s opinion, rilpivirine and the Quad pill
containing Truvada and elvitegravir have the strongest chance of commercial
success.
Given the growing concerns over nucleoside toxicity, Datamonitor believes
development of a nucleoside-sparing fixed dose combination, such as an
integrase inhibitor and a protease inhibitor, may be the best strategy to
challenge Gilead' s market dominance.
Key reasons to purchase this research
- Understand the changing market dynamics of HIV drugs, success factors for
leading brands and the commercial potential of late stage pipeline products
- Assess the impact of events such as patent expiries and new product
launches on individual brands and the overall antiretroviral market.
- Obtain full global, country, class and product-specific forecasts of
currently marketed and pipeline antiretrovirals from 2008 to 2018.
| 
View Cart
